There were a few of points in the presentation I found interesting.
Slide 5: The COVID-19 diagnostics venture has been placed within the Lyramid business division, which is an obvious fit.
Slide 8: Expansion of the product range and market geographies is planned. I wonder what the source might be of the intended rapid PCR tests. Which geographies?
Slide 6: The proportioning of annual revenues is informative. With Slide 7 indicating Consumer Health to remain unchanged from FY2019, the implication is that a 50+% Biotech revenue increase is anticipated for FY2020.
Slide 19: An upcoming milestone is Antibody test sales and commercial partnerships. I wonder what type of partnership(s) is envisaged.
With a managerial appointment as well the Company clearly has a confident view on the viability of the new diagnostics push.
Did anyone registered for the Meeting pick up any points of note?
- Forums
- ASX - By Stock
- AN1
- Ann: General Meeting Presentation
Ann: General Meeting Presentation, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $11.01K | 1.376M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 123437 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 80000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 123437 | 0.008 |
1 | 1091271 | 0.007 |
3 | 565639 | 0.006 |
1 | 300000 | 0.005 |
3 | 825000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 80000 | 1 |
0.010 | 157763 | 1 |
0.013 | 750000 | 1 |
0.015 | 340000 | 2 |
0.016 | 100000 | 1 |
Last trade - 12.36pm 23/08/2024 (20 minute delay) ? |
AN1 (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online